Selective TASK‑1 Inhibitor with a Defined Structure–Activity Relationship Reduces Cancer Cell Proliferation and Viability حسب Bárbara Arévalo (4053358)

"…Mutation of seven residues to A (I118A, L122A, F125A, Q126A, L232A, I235A, and L239A) markedly decreased the F3-induced inhibition of TASK-1 channels, consistent with the molecular modeling predictions. …"

Bacterial growth load (CFUs) and average of NH₃ ppm across the cage-change cycle in cages changed bi-weekly (filled circles) vs. weekly (open circles). حسب B. Ulfhake (6293984)

الموضوعات:

K562 cells were treated with 40 nM of miR-214 mimics or a negative mimics control for 24 h, followed by treatment with 50 μM of hemin for 48 h. حسب Tipparat Penglong (164413)

Boxplots of average NH₃ ppm in cages with four female or four male mice (see key for male and female) across five cage changing cycles at KI, LUMC and UGA. حسب B. Ulfhake (6293984)

الموضوعات:

Atomically Precise Au₄₂ Nanorods with Longitudinal Excitons for an Intense Photothermal Effect حسب Yingwei Li (701628)

الموضوعات:

Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 Diabetes حسب Yun Wu (150224)

الموضوعات:

Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 Diabetes حسب Yun Wu (150224)

الموضوعات:

Pulse Ultrasound-Based Response Enhancement of a MOX Gas Sensor حسب Yumin Yang (5737235)

"…For 2 ppm methanol, the RE by the pulse ultrasound is 50%, relative to the continuous ultrasound, when the pulse width, duty ratio, and working frequency are 0.4 ms, 50%, and 110.1 kHz, respectively. …"

Pulse Ultrasound-Based Response Enhancement of a MOX Gas Sensor حسب Yumin Yang (5737235)

"…For 2 ppm methanol, the RE by the pulse ultrasound is 50%, relative to the continuous ultrasound, when the pulse width, duty ratio, and working frequency are 0.4 ms, 50%, and 110.1 kHz, respectively. …"

VPS34 inhibition decreases intracellular levels of cholesteryl-esters, blocks cholesterol uptake and enhances lysosomal degradation of LDLR. حسب Marek J. Kobylarz (9292599)

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease حسب Yi Sun (118759)

"…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …"

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease حسب Yi Sun (118759)

"…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …"

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease حسب Yi Sun (118759)

"…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …"

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease حسب Yi Sun (118759)

"…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …"

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease حسب Yi Sun (118759)

"…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …"

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease حسب Yi Sun (118759)

"…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …"

PPM1A is indispensable for murine intestinal regeneration upon colitis. حسب Ruyuan Zhou (10197187)

siRNA Knockdown of PKCδ decreases phosphorylation of VEEV capsid. حسب Brian D. Carey (6092747)

Does Mean Platelet Volume Decrease in the presence of Coronary Artery Fistula? حسب Isa Sincer (7234577)

"…<div><p>Abstract Background: Coronary artery fistula (CAF) is an abnormal connection that links a coronary artery to a cardiac chamber or another major blood vessel. …"

Table_1_Decreased Risk in the Pancreatic Cancer With History of Hay Fever: A Meta-Analysis.doc حسب Guannan Wang (2209297)

"…A history of hay fever was associated with a decreased risk of pancreatic cancer (OR, 0.57; 95% CI, 0.50–0.64, P < 0.00001) through fixed effect model.…"